Source comparison
LL-37 BPC-157 Protocol Chronic Infection: Treatment Approach Comparison
Antibiotics alone Bacterial cell wall or protein synthesis inhibition Minimal. Biofilm reduces penetration 100–1,000× None. May worsen dysbiosis None. Fibrosis persists 40–50% Suppresses symptoms without addressing structural barriers; effective for acute infe
This comparison does not assign a generated winner or score.
- Antibiotics alone
- Bacterial cell wall or protein synthesis inhibition
- Minimal. Biofilm reduces penetration 100–1,000×
- None. May worsen dysbiosis
- None. Fibrosis persists
- 40–50%
- Suppresses symptoms without addressing structural barriers; effective for acute infection, inadequate for biofilm-mediated chronic infection
- LL-37 monotherapy
- Membrane disruption, biofilm EPS degradation, immune cell chemotaxis
- High. 60–80% biofilm reduction in 24hr
- Moderate. Recruits neutrophils and macrophages
- None. Does not address fibrosis or angiogenesis
- 25–35%
- Clears biofilm and restores immune presence but fails to repair tissue damage that allows recolonisation
- BPC-157 monotherapy
- Angiogenesis (VEGF upregulation), cytokine modulation (TNF-alpha, IL-6 reduction)
- None. No direct antimicrobial or biofilm activity
- Moderate. Reduces inflammation without immunosuppression
- High. Increases capillary density 40–60%
- 50–60%
- Improves tissue quality and reduces pain but cannot resolve active infection without antimicrobial pressure
- LL-37 + BPC-157 combined protocol
- Biofilm disruption (LL-37) + tissue repair and immune optimisation (BPC-157)
- High. Biofilm cleared, immune cells gain tissue access
- High. Recruits immune cells and modulates inflammatory environment
- High. Angiogenesis and fibrosis reduction restore tissue function
- 10–15%
- Addresses both structural (biofilm, fibrosis) and immunological (cytokine dysregulation, poor vascularisation) barriers; most complete approach for treatment-resistant chronic infection
- LL-37 + BPC-157 + antibiotics (sequential)
- Combined antimicrobial, biofilm disruption, immune restoration, tissue repair
- Very high. Peptides precondition site, antibiotics penetrate disrupted biofilm
- Very high. Coordinated immune recruitment and pathogen suppression
- High. BPC-157 continues post-antibiotic to complete repair
- 8–12%
- Gold standard in observational case series; sequential administration (peptides 48–72hr before antibiotics) produces synergistic effect and lowest documented relapse rate